Company: SWAGW
Filing Date: 2025-04-14
Form Type: 10-K
Source: 0001213900-25-031596
Chunk: 231

Company: Stran & Company, Inc.
Filing Date: 2025-04-14
Form: 10-K
Item: Item 1A
Chunk 231
---
 the plan. On March 3, 2025, the Hearings Panel informed the Company
that it determined to grant the Company’s request to continue its listing on Nasdaq subject to three conditions. The first was that
the Company become current on its financial filings. The second was that the Company meet the Nasdaq minimum closing bid price requirement.
The third was that the Company hold its annual shareholder meeting for 2024.

In accordance with the Company’s presentation
at the hearing, on February 11, 2025, the Company filed its Quarterly Reports on Forms 10-Q for the periods ended March 31, 2024 and June
30, 2024. On March 7, 2025, the Company filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. As a result,
the Company has regained compliance with the Filing Rule. On February 20, 2025, the Company received a written notification from the Staff
notifying the Company that for the last 11 consecutive business days, from February 4, 2025 to February 19, 2025, the closing bid price
of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company regained compliance with the Bid
Price Rule. In addition, the Company will schedule its annual meeting for 2024 and 2025 to take place in the second quarter of 2025. Upon
the conclusion of such annual meeting, the Company will regain compliance with the Annual Meeting Rule.

Although we have regained compliance with the
Filings Rule and the Bid Price Rule, no assurance can be provided that we will regain compliance with the Annual Meeting Rule or otherwise
remain in compliance with the Nasdaq Listing Rules. In addition, our board of directors may determine that the cost of maintaining our
listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock and publicly-traded
warrants from Nasdaq may materially impair our stockholders’ ability to buy and sell our common stock and publicly-traded warrants
and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock and publicly-traded
warrants. The delisting of our common stock and publicly-traded warrants could also significantly impair our ability to raise capital
and the value of your investment.

Our publicly-traded warrants may not have
any value.

Our publicly-traded